Genomics plc, a leading analysis company developing algorithms, data resources and software solutions to uncover the relationships between genetic variation and human disease, today announced that Vertex Pharmaceuticals will use Genomics’ integrated database and state-of-the-art analysis tools to inform its drug research and development.
These tools aim to provide confidence in the rationale for targeting Vertex’s pathways of interest for the treatment of certain diseases and to identify potential safety concerns and repositioning opportunities.
Genomics has developed a unique analytical platform for genome analysis and interpretation. The platform combines proprietary algorithms and software with the company’s integrated genome-phenome database and analytical expertise to learn about human biology. Genomics has several existing partnerships with large pharmaceutical companies, and in clinical genomics is a Platform Partner for Genomics England, the company undertaking the 100,000 Genomes Project in the UK.
John Colenutt, CEO, Genomics plc, said: “Pharmaceutical and biotech companies are increasingly using human genetic data in research to increase the chance of success in drug development. We are excited that Vertex has chosen to use Genomics’ proprietary technology, integrated database and tools to support them in this aim.”
Paul de Bakker, PhD, Head of Computational Genomics for Vertex, said: “Vertex is focused on advancing research programmes where disease mechanisms are validated by human biology. Our collaboration with Genomics is aimed at obtaining insights into the genetic underpinnings of specific targets and diseases to help predict which potential medicines may have success moving from discovery research toward patients.”